Diabetes news, Dexcom, ViaCyte, Lilly

5

NEWS

Funds for

ViaCyte 'cure'

ViaCyte has closed a $45m Series

D financing tranche in the United

States, bringing the total round

to more than $115m, reports

DrugDeliveryBusiness.com. The

funding will be allocated to ViaCyte's

advanced portfolio of cell-derived

therapies designed to provide a

functional cure for people with

Type 1 diabetes. The company is

advancing a Phase II clinical study on

the PEC-Encap product candidate, a

treatment comprised of pancreatic

islet precursor cells encapsulated in a

novel membrane. ViaCyte developed

PEC-Encap in partnership with

W.L. Gore & Associates and remains

on schedule to provide data on its

second Phase II product candidate,

PEC-Direct, in the first half of 2022,

Dexcom API

nod from FDA

By Ricky Zipp writing for

MedTechDive July 2021, "Dexcom

wins FDA nod for real-time artificial

pancreas systems (APIs), allowing

third-party developers access to

CGM data of Dexcom users. Dexcom

contends that the APIs will help

patients and healthcare providers

as both treatment information and

patient-specific CGM information

will be in one place and allow

for 'in-the-moment' diabetes

management coaching and feedback.

Developers can integrate CGM data

with their applications, diabetes

management systems or devices

through the new APIs, according

to the announcement. Diabetes

management companies like Teladoc

Health's Livongo for Diabetes and the

smartwatch maker Garmin are in the

testing and development phase of

syncing their products with Dexcom

users' sensor data. To read more

CLICK HERE.

Lilly buys 'smart insulin'

company

In July 2021 Eli Lilly and Company announced the acquisition of Protomer

Technologies ("Protomer"), a private biotech company. Protomer's

proprietary peptide- and protein-engineering platform is used to identify

and synthesize molecules that can sense glucose or other endogenous

modulators of protein activity.

Founded in 2015 and based in Pasadena, California, Protomer is

engineering next-generation protein therapeutics that can sense molecular

activators in the body. The company's proprietary chemical biology-based

platform enables the development of therapeutic peptides and proteins with

tunable activity that can be controlled using small molecules. Protomer has

used this approach toward advancing a portfolio of therapeutic candidates,

including glucose-responsive insulins that can sense sugar levels in the

blood and automatically activate as needed throughout the day.

Ruth Gimeno, vice president, diabetes research and clinical investigation

at Lilly commented, "Lilly has long strived to make life better for people

living with diabetes and we have a continued determination to provide real

solutions, including innovation in insulin therapy. Glucose-sensing insulin

is the next frontier and has the potential to revolutionize the treatment

and quality of life of people with diabetes by dramatically improving both

therapeutic efficacy and safety of insulin therapy. Protomer's glucosesensing insulin program,

based on its proprietary molecular engineering of

protein sensors (MEPS) platform, is showing significant promise and Lilly

is excited to enhance our diabetes pipeline with the company's innovative

technology."

To read more, CLICK HERE.

with preliminary data set to be

presented at the American Diabetes

Association Scientific Sessions later

this month.

"There have been few paradigmshifting

innovations in the 100

years since the discovery of insulin.

ViaCyte's portfolio of stem cellderived

therapies are first-incategory,

first-in-class products that

represent major advances in finding

a functional cure for Type 1 diabetes

and other chronic diseases in the

future," ViaCyte president and CEO

Michael Yang said in the release.

"This financing should allow us to

accelerate the development of our

three novel approaches to reduce

the burden faced by people with

Type 1 diabetes. With several of our

therapies already in the clinic, we

look forward to an exciting year of

progress in our clinical trials."

ViaCyte's stem cell-derived islet cell replacement therapies are being

developed to treat insulin-requiring diabetes.

Index

  1. Free online Desang diabetes magazine, diabetes information
  2. Free online Desang diabetes magazine, diabetes information
  3. Free online Desang diabetes magazine, diabetes information
  4. Diabetes news, Walmart's own insulin, investment for Fractly
  5. Diabetes news, Dexcom, ViaCyte, Lilly
  6. diabetes news
  7. Menarini GlucoMen Day, CGM, needle-free, Type 1 diabetes, smart CGM, Menarini diabetes care
  8. diabetes news, Libre cgm reduces diabetes distress
  9. Medtrum A6 Touchcare Nano patch pump and CGM in harmony
  10. Dexcom G6 CGM, continuous glucose monitoring, Dexcom G7, Kevin Sayer
  11. NHS diabetes
  12. Dexcom CGM G6, continuous glucose monitoring
  13. Dexcom G6 CGM, continuous glucose monitoring
  14. diabetic food news
  15. Abbott Freestyle Libre 2, Flash Glucose Monitoring, FSL2, Abbott Wellness Factory
  16. medical sensors, medical cgm, idtechex
  17. insulin in type 2 diabetics, quality in diabetes care
  18. medical sensors, medical cgm, idtechex, hypo metrics
  19. scensia Contour Next One Diabetes blood test meters
  20. Desang diabetes magazine, my diabetes kit, Tandem t-slim insulin pump
  21. Desang diabetes magazine, my diabetes kit, Tandem t-slim insulin pump
  22. free diabetes healthcare magazine
  23. free diabetes healthcare magazine
  24. Omnipod ambassador Khalid Keshta
  25. Omnipod ambassador Khalid Keshta
  26. insulin pump, Dana RS system, artificial pancreas, Advanced Therapeutics UK, CamAPS FX, Dexcom G6
  27. insulin pump, Dana RS system, artificial pancreas, Dana Diabecare, Advanced Therapeutics UK, SOOIL D
  28. insulin pump, Dana RS system, artificial pancreas, Dana Diabecare, Advanced Therapeutics UK, SOOIL D
  29. Diabetes technology education from Diabetes Technology Network DTN
  30. matthews cotswold flour
  31. Desang diabetes, Inside Diabetes guides, guide to injecting insulin, guide to injecting for people w
  32. Medtronic MiniMed 780G System Automated for an easier way to stabilise glucose levels.
  33. matthews cotswold flour
  34. diabetes food news
  35. diabetes food news, pesky fish, the cornish fishmonger, brighton and hove fish
  36. diabetes food news, the whitby catch, Wright Bros, Bart Van Oolfen
  37. Insulet Omnipod DASH insulin pump with insulin pods, podders, Omnipod DASH Personal Diabetes Manager
  38. diabetes food news, Bart Von Oolfen
  39. BD, Becton Dickinson, injection technique, BD pen needles, BD and Me
  40. Desang Diabetes Magazine, Making Carbs Count, carbohydrate counting for diabetes
  41. Desang Diabetes Magazine, Making Carbs Count, carbohydrate counting for diabetes
  42. Desang Diabetes Magazine, Making Carbs Count, carbohydrate counting for diabetes
  43. Desang diabetes kitbags
  44. Desang diabetes magazine, free diabetes magazine, living with diabetes, diabetic diet, carb counting

Related Issues